An overview of our work

Our mission is to reduce the burden of malaria in disease-endemic countries by discovering, developing and facilitating delivery of new, effective and affordable antimalarial drugs.

Our vision is a world in which these innovative medicines will cure and protect the vulnerable and under-served populations at risk of malaria, and help to ultimately eradicate this terrible disease.


MMV is a leading product development partnership (PDP) in antimalarial drug research.

MMV and partners manage a portfolio of over 65 projects, the largest portfolio of antimalarial R&D and access projects ever assembled. The 2021 portfolio includes eleven compounds in clinical development addressing unmet medical needs in malaria, including medicines for children, pregnant women and relapsing malaria, and drugs that could support the elimination/eradication agenda.

Since its foundation in 1999, MMV and partners have developed and brought forward eleven new medicines, with two more added to the portfolio post-approval. These include:

The impact of these new antimalarials has been impressive. In total, an estimated 2.7 million lives have been saved by the medicines supported by MMV and partners.

→Take a look at MMV's milestones for more information on key programmes and achievements 

→Take a look at MMV's products and projects page for more information on each product


 1. Trademarks owned or licensed by GSK